CN1272010C - 粉末状吸入剂组合物 - Google Patents

粉末状吸入剂组合物 Download PDF

Info

Publication number
CN1272010C
CN1272010C CNB03813845XA CN03813845A CN1272010C CN 1272010 C CN1272010 C CN 1272010C CN B03813845X A CNB03813845X A CN B03813845XA CN 03813845 A CN03813845 A CN 03813845A CN 1272010 C CN1272010 C CN 1272010C
Authority
CN
China
Prior art keywords
inflammatory agent
lactose
specifiable
powdery
water activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB03813845XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1662244A (zh
Inventor
宫台信男
冈田实
堀江敏彰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Shinyaku Co Ltd
Original Assignee
Jiuguang Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiuguang Pharmaceutical Co ltd filed Critical Jiuguang Pharmaceutical Co ltd
Publication of CN1662244A publication Critical patent/CN1662244A/zh
Application granted granted Critical
Publication of CN1272010C publication Critical patent/CN1272010C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB03813845XA 2002-06-14 2003-06-13 粉末状吸入剂组合物 Expired - Lifetime CN1272010C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP174402/2002 2002-06-14
JP2002174402A JP3691459B2 (ja) 2002-06-14 2002-06-14 粉末状吸入剤組成物

Publications (2)

Publication Number Publication Date
CN1662244A CN1662244A (zh) 2005-08-31
CN1272010C true CN1272010C (zh) 2006-08-30

Family

ID=29727967

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB03813845XA Expired - Lifetime CN1272010C (zh) 2002-06-14 2003-06-13 粉末状吸入剂组合物

Country Status (9)

Country Link
US (1) US20050163724A1 (enExample)
EP (1) EP1514549A4 (enExample)
JP (1) JP3691459B2 (enExample)
KR (1) KR20050008739A (enExample)
CN (1) CN1272010C (enExample)
AU (1) AU2003242369A1 (enExample)
CA (1) CA2488026A1 (enExample)
TW (1) TW200402313A (enExample)
WO (1) WO2003105859A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0019172D0 (en) * 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6777399B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
CO5310534A1 (es) * 2000-08-05 2003-08-29 Glaxo Group Ltd Nuevos derivados de androstano anti-inflamatorios
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
ES2314052T3 (es) 2001-04-30 2009-03-16 Glaxo Group Limited Derivados de ester de 17beta-carbotioato de androstano con un grupo ester ciclico en la posicion 17alfa.
US20040248867A1 (en) * 2001-06-12 2004-12-09 Keith Biggadike Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives
US20050175545A1 (en) * 2002-02-04 2005-08-11 Keith Biggadike Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0507165D0 (en) * 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
PE20090907A1 (es) * 2007-07-21 2009-08-05 Boehringer Ingelheim Int Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente
UA118861C2 (uk) * 2013-12-06 2019-03-25 Оріон Корпорейшн Спосіб отримання сухих порошкових композицій для інгаляцій

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6034925B2 (ja) * 1979-07-31 1985-08-12 帝人株式会社 持続性鼻腔用製剤およびその製造法
JPH07116215B2 (ja) * 1989-04-19 1995-12-13 エスエス製薬株式会社 新規なステロイド化合物
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
US5767152A (en) * 1995-05-04 1998-06-16 Nielsen; Thor Bagger Composition and methods for stimulating hair growth
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
GB9925934D0 (en) * 1999-11-03 1999-12-29 Glaxo Group Ltd Novel apparatus and process
SE0002822L (sv) * 2000-08-04 2002-01-29 Microdrug Ag Elektropulver
AU2001283438A1 (en) * 2000-08-21 2002-03-04 Aeropharm Technology Incorporated A method of stabilizing a dry powder pharmaceutical formulation
CA2416563A1 (en) * 2000-09-12 2002-03-21 Pharmacia & Upjohn Company Pharmaceutical composition having specific water activity
JP3691487B2 (ja) * 2000-12-22 2005-09-07 久光メディカル株式会社 炎症性気道疾患の予防・治療剤

Also Published As

Publication number Publication date
KR20050008739A (ko) 2005-01-21
US20050163724A1 (en) 2005-07-28
JP2004018440A (ja) 2004-01-22
TW200402313A (en) 2004-02-16
EP1514549A1 (en) 2005-03-16
CN1662244A (zh) 2005-08-31
EP1514549A4 (en) 2011-06-08
WO2003105859A1 (ja) 2003-12-24
TWI309985B (enExample) 2009-05-21
CA2488026A1 (en) 2003-12-24
AU2003242369A1 (en) 2003-12-31
JP3691459B2 (ja) 2005-09-07

Similar Documents

Publication Publication Date Title
CN1272010C (zh) 粉末状吸入剂组合物
ES2762806T3 (es) Tratamiento utilizando estabilizadores de mastocitos para trastornos sistémicos
CN1805730A (zh) 鼻用药物制剂和使用方法
CN1115152C (zh) 用尿苷三磷酸及相关化合物治疗支气管炎的方法
JP2014525471A (ja) 咳および咳発作の治療
JP2003510275A (ja) ロテプレドノールと抗ヒスタミン薬の新規な組み合わせ物
CN1939534A (zh) 含有人生长激素或人粒细胞巨噬细胞刺激因子的用于治疗损伤和溃疡的外用制剂
CA3160114A1 (en) New multi-functional oligopeptides
WO2024169972A1 (en) New multi-functional oligopeptides
JP2021506897A (ja) フドステインのエアロゾル吸入用溶液製剤及びその製造方法
WO2022193185A1 (en) New conjugates
AU2020396818A1 (en) New conjugates of peptides and polysaccharide
CN104098491B (zh) 一种乙酰半胱氨酸化合物及含有该化合物的吸入用乙酰半胱氨酸溶液
US20220105082A1 (en) New formulations containing leukotriene receptor antagonists
CN1168496C (zh) 胰岛素肺部给药的粉雾剂及其制备方法
CN105407884B (zh) 降低甘油三酯、总胆固醇和低密度脂蛋白血液浓度的方法
CN1439360A (zh) 有效部位药物沉积得到改善的干粉组合物
WO2022224030A1 (en) Dry powder inhalation (dpi) formulation
CN111110634A (zh) 一种磷酸氯喹吸入气雾剂及其制备方法
CN101045158A (zh) 胰岛素类似物干粉组合物及其制备方法
CN101474399A (zh) 一种胰岛素肺吸入粉雾剂及其制备方法
CN107126421A (zh) 一种氢溴酸右美沙芬咀嚼片
KR102250876B1 (ko) 티오트로피움 또는 이의 약학적으로 허용가능한 염을 포함하는 흡입용 건조분말 조성물
CN1814281A (zh) 鲑降钙素吸入粉雾剂及其制备方法
WO2019005901A1 (en) Liponucleotide-based therapy for asthma

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: JAPAN NEW MEDICINE CO., LTD.

Free format text: FORMER OWNER: SSP CO., LTD.

Effective date: 20070511

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20070511

Address after: Kyoto Japan

Patentee after: NIPPON SHINYAKU Co.,Ltd.

Address before: Tokyo, Japan

Patentee before: Jiuguang Pharmaceutical Co.,Ltd.

CX01 Expiry of patent term

Granted publication date: 20060830

CX01 Expiry of patent term